QL Biopharmaceutical Co Revenue
Pharmaceutical Manufacturing • 
20 Life Science Park Road, Building 7, China • 1-10 Employees
$
QL Biopharmaceutical Co revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Key Contact at QL Biopharmaceutical Co
Andrew Leger
Executive Director & Head of US BD
Company overview
| Headquarters | 20 Life Science Park Road, Building 7, #101, Beijing, 102206, CN |
| Website | |
| NAICS | 3254 |
| Founded | 2018 |
| Employees | 1-10 |
About QL Biopharmaceutical Co
Founded in 2018, QL Biopharm specializes in the research, development, and manufacturing of recombinant protein therapeutics. The company is committed to developing innovative biologic medicines for the treatment of chronic metabolic diseases such as diabetes, obesity, and MASH, aiming to improve the quality of life for people worldwide.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Head
Funding Data
QL Biopharmaceutical Co has never raised funding before.
United Kingdom
Australia
Korea, Republic of
South Africa
Frequently asked questions
QL Biopharmaceutical Co is located in 20 Life Science Park Road, Building 7, CN.
QL Biopharmaceutical Co generates an estimated annual revenue of $171,110. This revenue figure reflects the company's market position and business performance in its industry.
QL Biopharmaceutical Co has an estimated valuation of $547,552. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
QL Biopharmaceutical Co was founded in 2018, making it 8 years old. The company has established itself as a significant player in its industry over this time.
QL Biopharmaceutical Co has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
